Has Roopesh Kantala, MD received payments from drug or device companies?

Yes. Drug and device makers reported $490,636 in general payments to Roopesh Kantala, MD across 1,552 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roopesh Kantala, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roopesh Kantala, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roopesh Kantala, MD

Medical Oncology · Mesa, AZNPI 1811922198

Payments from drug & device makers

$490,636in general payments, 2019–2025

Across 1,552 payments — averaging $316.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$223K
Regeneron Healthcare Solutions, Inc.$102K
Sanofi$45K
Takeda Pharmaceuticals U.S.A., Inc.$20K
AstraZeneca$19K
E.r. Squibb & Sons, L.L.C.$12K
plus $69K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	348	$223,396
Regeneron Healthcare Solutions, Inc.	111	$101,772
Sanofi	61	$45,110
Takeda Pharmaceuticals U.S.A., Inc.	25	$20,405
AstraZeneca(2 entities)	85	$19,232
E.r. Squibb & Sons, L.L.C.	102	$11,831
Pfizer	71	$11,593
Seagen Inc.	24	$7,214
Pharmacosmos Therapeutics Inc.	12	$6,654
Incyte Corporation	37	$5,897
Karyopharm Therapeutics Inc.	8	$5,180
Bristol Myers Squibb	57	$4,364
Clovis Oncology, Inc.	13	$3,861
Bayer	15	$3,488
AbbVie	29	$2,217
Beone Medicines USA, Inc.	2	$1,974
Rigel Pharmaceuticals, Inc.	20	$1,969
Johnson & Johnson	62	$1,420
Novartis	88	$1,407
Taiho Oncology, Inc.	1	$1,400
Blueprint Medicines Corporation	10	$1,185
Merck	42	$814
Daiichi Sankyo Inc.	28	$796
Geron Corporation	1	$780
Genentech USA, Inc.	43	$754
Gilead(2 entities)	36	$691
Pharmacyclics LLC, An Abbvie Company	20	$514
GSK	23	$509
Amgen	30	$506
Astellas Pharma US Inc	16	$335
Eisai Inc.	15	$318
Puma Biotechnology, Inc.	12	$236
Caris MPI, Inc.	1	$220
Sobi, Inc	2	$217
Array Biopharma Inc	12	$191
Genmab U.S., Inc.	7	$180
Mirati Therapeutics, Inc.	9	$164
Tempus AI, Inc	3	$158
Ipsen Biopharmaceuticals, Inc	9	$157
EMD Serono, Inc.	8	$151
Boehringer Ingelheim	5	$119
Fennec Pharmaceuticals, Inc.	3	$117
Aurobindo Pharma USA, Inc.	2	$113
Beigene USA, Inc.	5	$110
AVEO Pharmaceuticals, Inc.	5	$106
Jazz Pharmaceuticals Inc.	4	$102
Sumitomo Pharma America, Inc.	3	$72
Sanofi-aventis U.S. LLC	1	$67
Secura Bio, Inc.	1	$66
Springworks Therapeutics, Inc.	3	$62
Sun Pharmaceutical Industries Inc.	2	$35
Dova Pharmaceuticals	2	$34
Hologic Sales And Service, LLC	1	$34
Tersera Therapeutics LLC	1	$32
Deciphera Pharmaceuticals Inc.	1	$31
G1 Therapeutics, Inc.	2	$30
Pharmaessentia USA Corporation	1	$28
Stemline Therapeutics Inc.	1	$28
Exelixis Inc.	1	$22
Immunomedics, Inc.	1	$22

How this compares

$490,636 in reported general payments places this provider in the 85th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$1,364,327

Medicare patients

465

Services billed

116,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Mesa

Nathaniel FastenbergMesa$141
Michael BookmanTucson$4.8M
Erkut BorazanciScottsdale$3.5M
Daniel von HoffScottsdale$2.5M
Jason SalganickPhoenix$1.6M
Allan Espinosa MorazanPrescott$1.1M
Iyad HamarnehPrescott$855K
Isaac BowmanGilbert$844K
Saba RadhiGilbert$540K
Mital PatelPhoenix$484K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →